Literature DB >> 17167034

Analysis of mammalian carboxylesterase inhibition by trifluoromethylketone-containing compounds.

Randy M Wadkins1, Janice L Hyatt, Carol C Edwards, Lyudmila Tsurkan, Matthew R Redinbo, Craig E Wheelock, Paul D Jones, Bruce D Hammock, Philip M Potter.   

Abstract

Carboxylesterases (CE) are ubiquitous enzymes that hydrolyze numerous ester-containing xenobiotics, including complex molecules, such as the anticancer drugs irinotecan (CPT-11) and capecitabine and the pyrethroid insecticides. Because of the role of CEs in the metabolism of many exogenous and endogenous ester-containing compounds, a number of studies have examined the inhibition of this class of enzymes. Trifluoromethylketone-containing (TFK) compounds have been identified as potent CE inhibitors. In this article, we present inhibition constants for 21 compounds, including a series of sulfanyl, sulfinyl, and sulfonyl TFKs with three mammalian CEs, as well as human acetyl- and butyrylcholinesterase. To examine the nature of the slow tight-binding inhibitor/enzyme interaction, assays were performed using either a 5-min or a 24-h preincubation period. Results showed that the length of the preincubation interval significantly affects the inhibition constants on a structurally dependent basis. The TFK-containing compounds were generally potent inhibitors of mammalian CEs, with Ki values as low as 0.3 nM observed. In most cases, thioether-containing compounds were more potent inhibitors then their sulfinyl or sulfonyl analogs. QSAR analyses demonstrated excellent observed versus predicted values correlations (r2 ranging from 0.908-0.948), with cross-correlation coefficients (q2) of approximately 0.9. In addition, pseudoreceptor models for the TKF analogs were very similar to structures and models previously obtained using benzil- or sulfonamide-based CE inhibitors. These studies indicate that more potent, selective CE inhibitors, containing long alkyl or aromatic groups attached to the thioether chemotype in TFKs, can be developed for use in in vivo enzyme inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17167034     DOI: 10.1124/mol.105.021683

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  16 in total

Review 1.  Carboxylesterase inhibitors.

Authors:  M Jason Hatfield; Philip M Potter
Journal:  Expert Opin Ther Pat       Date:  2011-05-24       Impact factor: 6.674

2.  Reactivity versus steric effects in fluorinated ketones as esterase inhibitors: a quantum mechanical and molecular dynamics study.

Authors:  Josep Rayo; Lourdes Muñoz; Gloria Rosell; Bruce D Hammock; Angel Guerrero; F Javier Luque; Ramon Pouplana
Journal:  J Mol Model       Date:  2010-07-31       Impact factor: 1.810

3.  Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A2.

Authors:  Varnavas D Mouchlis; Christophe Morisseau; Bruce D Hammock; Sheng Li; J Andrew McCammon; Edward A Dennis
Journal:  Bioorg Med Chem       Date:  2016-05-10       Impact factor: 3.641

4.  Global and local molecular dynamics of a bacterial carboxylesterase provide insight into its catalytic mechanism.

Authors:  Xiaozhen Yu; Sara C Sigler; Delwar Hossain; Monika Wierdl; Steven R Gwaltney; Philip M Potter; Randy M Wadkins
Journal:  J Mol Model       Date:  2011-11-30       Impact factor: 1.810

5.  In Silico Design and Evaluation of Carboxylesterase Inhibitors.

Authors:  Shana V Stoddard; Xiaozhen Yu; Philip M Potter; Randy M Wadkins
Journal:  J Pest Sci (2004)       Date:  2010       Impact factor: 5.918

6.  Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619.

Authors:  C J Hillard; W-Sv Ho; J Thompson; K M Gauthier; C E Wheelock; H Huang; B D Hammock
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

7.  Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen").

Authors:  M Jason Hatfield; Lyudmila G Tsurkan; Janice L Hyatt; Carol C Edwards; Andrew Lemoff; Cynthia Jeffries; Bing Yan; Philip M Potter
Journal:  J Nat Prod       Date:  2013-01-03       Impact factor: 4.050

8.  Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity.

Authors:  Latorya D Hicks; Janice L Hyatt; Shana Stoddard; Lyudmila Tsurkan; Carol C Edwards; Randy M Wadkins; Philip M Potter
Journal:  J Med Chem       Date:  2009-06-25       Impact factor: 7.446

9.  Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH).

Authors:  Craig E Wheelock; Kosuke Nishi; Andy Ying; Paul D Jones; Michael E Colvin; Marilyn M Olmstead; Bruce D Hammock
Journal:  Bioorg Med Chem       Date:  2007-11-26       Impact factor: 3.641

10.  Development of amide-based fluorescent probes for selective measurement of carboxylesterase 1 activity in tissue extracts.

Authors:  Sean D Kodani; Morgane Barthélemy; Shizuo G Kamita; Bruce Hammock; Christophe Morisseau
Journal:  Anal Biochem       Date:  2017-10-18       Impact factor: 3.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.